Bernard Laurel appointed as the President of Piomic Medical Inc.

M&A experienced advanced wound care leader appointed as President of US Subsidiary Piomic Medical Inc.

M&A experienced advanced wound care leader appointed as President of US Subsidiary Piomic Medical Inc.

Zurich, Switzerland – 02 February 2023 – Piomic Medical, at the forefront of innovation in the treatment of hard-to-heal wounds and management of surgical site infections, today announces the appointment of Bernard Laurel as the President of Piomic Medical Inc. Mr. Laurel. is a highly experienced global business executive with an exceptional track record of managing, scaling and supporting the acquisition of market leaders in the wound care industry.

“Bernard will be a critical member of our Executive Management team as we prepare for the potential commercial launch of COMS® in North America.” states Bertrand Hughes, Chairman of the Board at Piomic Medical. “His extensive experience in scaling emerging medtech companies and guiding them to successful strategic transactions will be invaluable as we initiate further clinical investigations in the US. Bernard’s previous experience in supporting clinical investigations for De-Novo technologies seeking FDA approval is very important to improve commercial readiness before Piomic Medical enters the US market. With his wealth of knowledge and experience, Bernard is sure to make a significant impact on the success of the company.“

Mr. Laurel adds: “I am excited to collaborate with the Piomic Medical Board and management team to bring COMS® therapy to patients and caregivers who need cost-effective, proven wound healing modalities. COMS® therapy is an innovative and promising intervention, especially for patients with diabetic foot ulcers that have not responded well to standard-of-care treatments. These wounds are difficult to heal and adversely impact U.S. society, most notably through the decreased quality of life, increased morbidity and mortality, and rising healthcare expenditures. Estimates suggest that chronic wound care costs the U.S. between 28 to 96 billion USD annually1. I am eager to support Piomic’s first pivotal clinical trial MAVERICKS in the U.S. to evaluate the benefits of COMS® therapy for recalcitrant DFUs. This trial represents one of the largest undertaken for medical devices in the advanced wound care industry during the past decade.

Mr. Laurel was President & CEO of Anodyne Medical Device (initially VP Sales & Marketing) from 2013 through 2018, a leading U.S. manufacturer and global supplier of pressure ulcer treatment and prevention devices. Success during his tenure across the P&L helped facilitate a lucrative acquisition by Hill-Rom in 2016. Prior to this, he was VP of Sales & Marketing with Sanuwave, a wound care company using sonic energy, where he supported a multicenter pivotal RCT in diabetic foot ulcers while expanding international distribution. At Medela, a Swiss-based leader in breast pumps and neonatal equipment, he supported the creation and growth of the company’s new wound care division. This startup business unit focused on negative pressure wound therapy (NPWT), with Mr. Laurel playing a key role in litigation that ended a multibillion-dollar monopoly in the advanced wound care space.

Mr. Laurel holds a BS in Biology from Duquesne University and an MBA in Business Administration from the Tepper School of Business at Carnegie Mellon University.

About Piomic Medical
There are about 50 million reported cases of patients suffering from hard-to-heal wounds, which has created a severe cost burden on global healthcare systems. The timely transfer of patients from stationary settings to less expensive post-acute care settings, such as the outpatient or home care setting, has become a top priority to reduce health care costs in developed countries. Piomic develops innovative medical devices for the treatment of hard-to-heal wounds, based on the proprietary COMS® therapy, which incorporates the technology for concurrent optical and magnetic stimulation. COMS® treatment requires minimizing training efforts and fits seamlessly into the workflow of healthcare professionals. As an adjunctive treatment, the application does not require any changes to standard of care protocols and fits well into phase-adapted wound-healing concepts. The simplicity of use of COMS® therefore allows it to be used easily across the continuum of care, from in-patient clinic to home care. Along with the possibility for self-administration, the COMS® One device offers optimal conditions to enable patient self-management in a cost-effective manner. A market need that could not have been demonstrated more clearly than during the COVID-19 pandemic.

Important Regulatory Disclaimers
The COMS One therapy system has not yet received regulatory approval in the U.S. and Canada. As such, use is limited to investigational use only in these regions. Any statement in this press release about the safety and effectiveness of the system does not apply to the U.S. and Canada because the device is currently undergoing clinical investigation in these geographies.

Reference List
1. Nussbaum SR, Carter MJ, Fife CE, et al. An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. Value Health. 2018;21(1):27-32.